Market cap
$12,561 Mln
Revenue (TTM)
$1,454 Mln
P/E Ratio
73.9
P/B Ratio
8.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$138 Mln
-
ROE
0.1 %
-
ROCE
-- %
-
Industry P/E
50.52
-
EV/EBITDA
55.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$4.3
-
Face value
--
-
Shares outstanding
39,331,425
10 Years Aggregate
CFO
$44.61 Mln
EBITDA
$247.81 Mln
Net Profit
$151.46 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Penumbra (PEN)
| 2.6 | -2.0 | -7.4 | 19.5 | 0.5 | 4.9 | 19.2 |
|
BSE Sensex
| -11.8 | -2.9 | -8.2 | -8.4 | 6.1 | 7.5 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Penumbra (PEN)
| 30.9 | -5.5 | 13.1 | -22.6 | 64.2 | 6.5 | 34.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Penumbra (PEN)
|
318.9 | 12,561.0 | 1,454.3 | 171.1 | 11.1 | 12.1 | 73.9 | 8.5 |
| 8.9 | 6,247.2 | 6,552.2 | -551.4 | -4.3 | -9.9 | -- | 1.0 | |
| 304.2 | 8,139.5 | 2,589.9 | 168.8 | 21.4 | 2.5 | 50.5 | 1.2 | |
| 57.2 | 8,964.6 | 3,458.5 | -11.6 | 2.6 | -0.6 | -- | 3.0 | |
| 110.3 | 6,409.9 | 551.4 | -189.3 | -15.6 | -26.3 | -- | 9.6 | |
| 104.8 | 3,743.0 | 787.9 | -27.8 | -2.7 | -19.6 | -- | 22.7 | |
| 96.6 | 6,465.0 | 1,546.2 | 279.0 | 15.0 | 23.9 | 23.7 | 5.3 | |
| 178.7 | 9,345.3 | 1,558.5 | 76.3 | 19.6 | 9.5 | 44.3 | 11.9 | |
| 60.9 | 3,761.8 | 1,542.8 | 139.3 | 12.1 | 8.8 | 27.2 | 2.3 | |
| 121.0 | 6,991.7 | 763.3 | 51.4 | 11.7 | 2.5 | 137.7 | 3.0 |
Shareholding Pattern
View DetailsAbout Penumbra (PEN)
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the... Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California. Read more
-
Co-Founder, Chairman, President & CEO
Mr. Adam Elsesser
-
Co-Founder & Director
Dr. Arani Bose M.D.
-
Headquarters
Alameda, CA
-
Website
FAQs for Penumbra (PEN)
What is the current share price of Penumbra Inc (PEN) Today?
The share price of Penumbra Inc (PEN) is $318.94 (NYSE) as of 02-Jun-2026 14:51 EDT. Penumbra Inc (PEN) has given a return of 0.5% in the last 3 years.
What is the current PB & PE ratio of Penumbra Inc (PEN)?
The P/E ratio of Penumbra Inc (PEN) is 73.93 times as on 29-May-2026, a 46 premium to its peers’ median range of 50.52 times.
The P/B ratio of Penumbra Inc (PEN) is 8.55 times as on 29-May-2026, a 182 premium to its peers’ median range of 3.03 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
68.93
|
8.58
|
|
2024
|
665.53
|
8.10
|
|
2023
|
108.66
|
8.38
|
|
2022
|
-4,322.18
|
8.66
|
|
2021
|
4,102.34
|
11.28
|
What is the 52 Week High and Low of Penumbra Inc (PEN)?
The 52-week high and low of Penumbra Inc (PEN) are Rs 362.41 and Rs 221.26 as of 03-Jun-2026.
What is the market cap of Penumbra Inc (PEN)?
Penumbra Inc (PEN) has a market capitalisation of $ 12,561 Mln as on 29-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Penumbra Inc (PEN)?
Before investing in Penumbra Inc (PEN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.